Assessment Status | Awaiting HTA submission from Applicant |
HTA ID | 22065 |
Drug | Olaparib |
Brand | Lynparza® |
Indication | As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. |
Assessment Process | |
Rapid review commissioned | 26/10/2022 |
Rapid review completed | 20/10/2022 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 26/10/2022 |
Pre-submission consultation with Applicant | 13/12/2022 |